Astrana Health (NASDAQ:ASTH) Coverage Initiated by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Astrana Health (NASDAQ:ASTH) in a report released on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $66.00 target price on the stock.

Other research analysts have also recently issued research reports about the stock. Stifel Nicolaus raised their price target on shares of Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. BTIG Research raised their price target on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. KeyCorp assumed coverage on shares of Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. Truist Financial increased their price objective on shares of Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Robert W. Baird increased their price objective on shares of Astrana Health from $54.00 to $67.00 and gave the stock an “outperform” rating in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $62.00.

Astrana Health Trading Down 1.9 %

NASDAQ:ASTH opened at $61.37 on Monday. Astrana Health has a 52 week low of $28.86 and a 52 week high of $63.20. The firm has a 50 day moving average of $52.60 and a 200 day moving average of $45.60. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $3.44 billion, a price-to-earnings ratio of 46.50, a PEG ratio of 2.20 and a beta of 1.21.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.01. The business had revenue of $486.30 million during the quarter, compared to analysts’ expectations of $440.68 million. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The business’s quarterly revenue was up 39.7% on a year-over-year basis. During the same quarter last year, the company posted $0.28 earnings per share. As a group, sell-side analysts anticipate that Astrana Health will post 1.33 earnings per share for the current fiscal year.

Institutional Trading of Astrana Health

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new position in Astrana Health in the third quarter valued at $34,000. Central Pacific Bank Trust Division purchased a new position in Astrana Health in the third quarter valued at $160,000. Granite Bay Wealth Management LLC purchased a new position in Astrana Health in the third quarter valued at $290,000. Handelsbanken Fonder AB purchased a new position in Astrana Health in the third quarter valued at $492,000. Finally, SG Americas Securities LLC purchased a new position in Astrana Health in the third quarter valued at $680,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.